Erratum: CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2011-2015 (Neuro-Oncology (2018) 20(4) DOI: 10.1093/neuonc/noy131);CBTRUS statistical report: Primary brain and other central nervous system tumors diagnosed in the United States in 2011-2015

Neuro-Oncology

Volumn 20, Issue , 2018, Pages iv1-iv86

  Ostrom, Quinn T ^a,b   Gittleman, Haley ^a,c   Truitt, Gabrielle ^a,c   Boscia, Alexander ^a,c   Kruchko, Carol ^a   Barnholtz Sloan, Jill S ^a,c  

^a Mission Officer of the Central Brain Tumor Registry of the United States   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGE; ATTITUDE TO HEALTH; BRAIN CANCER; BRAIN TUMOR; CANCER INCIDENCE; CANCER REGISTRY; CENTRAL NERVOUS SYSTEM CANCER; CENTRAL NERVOUS SYSTEM TUMOR; EMBRYONAL TUMOR; GENDER; GLIOBLASTOMA; GLIOMA; GROUPS BY AGE; HISPANIC; HISTOPATHOLOGY; HUMAN; MALIGNANT MENINGIOMA; MENINGIOMA; MORTALITY RATE; PUERTO RICO; RACE; REVIEW; RURAL AREA; SPINAL CORD TUMOR; SURVIVAL RATE; UNITED STATES; URBAN AREA; ADOLESCENT; BRAIN; INCIDENCE; PATHOLOGY; REGISTER;

ADOLESCENT; BRAIN; BRAIN NEOPLASMS; CENTRAL NERVOUS SYSTEM NEOPLASMS; HUMANS; INCIDENCE; REGISTRIES; UNITED STATES;

EID: 85054487259     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/noy171     Document Type: Erratum

References (105)

1. Kruchko C, Ostrom QT, Gittleman H, Barnholtz-Sloan JS. The CBTRUS story: Providing accurate population-based statistics on brain and other central nervous system tumors for everyone. Neuro Oncol. 2018;20(3):295-298.
2. Louis D, Wiestler O, Cavanee W, eds. WHO Classification of Tumours of the Central Nervous System. Lyon, France: International Agency for Research on Cancer; 2007.
3. Ostrom QT, Gittleman H, Liao P, et al. CBTRUS Statistical Report: Primary brain and central nervous system tumors diagnosed in the United States in 2007-2011. Neuro Oncol. 2014; 16(s4):iv1-iv63.
4. Centers for Disease Control and Prevention (CDC). National Program of Cancer Registries Cancer Surveillance System Rationale and Approach. 1999; http://www.cdc.gov/cancer/npcr/pdf/npcr_css.pdf.
5. Cancer Registries Amendment Act, 102nd Cong. § 515 (1992). http:// www.gpo.gov/fdsys/pkg/STATUTE-106/pdf/STATUTE-106-Pg3372.pdf.
6. Benign Brain Tumor Cancer Registries Amendment Act, 107th Cong. § 260 (2002). http://www.gpo.gov/fdsys/pkg/PLAW-107publ260/pdf/ PLAW-107publ260.pdf.
7. National Cancer Institute. Overview of the SEER Program. http://seer. cancer.gov/about/overview.html.
8. Wöhrer A, Waldhör T, Heinzl H, et al. The Austrian Brain Tumour Registry: A cooperative way to establish a population-based brain tumour registry. J Neurooncol. 2009;95(3):401-411.
9. Asklund T, Malmstrom A, Bergqvist M, Bjor O, Henriksson R. Brain tumors in Sweden: Data from a population-based registry 1999-2012. Acta Oncologica. 2015; 54(3):377-384.
10. U.S. Cancer Statistics Working Group. United States Cancer Statistics: 1999-2015 Incidence and Mortality Web-based Report. Available from URL: Http://www.cdc.gov/uscs.
11. Fritz A, PC, Jack A, Shanmugaratnam K, Sobin L, Perkin DM, Whelan S, eds. International Classification of Diseases for Oncology, Third edition. World Health Organization; 2000.
12. Surveillance Epidemiology and End Results (SEER) Program. Number of Persons by Race and Hispanic Ethnicity for SEER Participants (2010 Census Data). 2015; http://seer.cancer.gov/registries/data.html.
13. Surveillance Epidemiology and End Results (SEER) Program. SEER∗Stat Database: Mortality - All COD, Aggregated With State, Total U.S. (1969- 2015) , National Cancer Institute, DCCPS, Surveillance Research Program, Surveillance Systems Branch, released April 2018. Underlying mortality data provided by NCHS (www. cdc.gov/nchs).
14. McCarthy BJ, Surawicz T, Bruner JM, Kruchko C, Davis F. Consensus conference on brain tumor definition for registration. November 10, 2000. Neuro Oncol. 2002;4(2):134-145. http://www.ncbi.nlm.nih.gov/ pubmed/11916506.
15. Surveillance Research Program - National Cancer Institute. ICCC Recode ICD-O-3/WHO. 2008. http://seer.cancer.gov/iccc/iccc-who2008.html.
16. Steliarova-Foucher E, Stiller C, Lacour B, Kaatsch P. International classification of childhood cancer, third edition. Cancer 2005; 103(7):1457-1467.
17. Swerdlow SH, Campo E, Harris NL, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, Fourth Edition. World Health Organization; 2007.
18. Kleihues P, Cavenee W, eds. Tumours of the Nervous System: World Health Organization Classification of Tumours. Lyon, France: IARC Press; 2000.
19. Louis DN, OH, Wiestler OD, Cavanee WK, eds. WHO Classification of Tumours of the Central Nervous System. Lyon, France: International Agency for Research on Cancer; 2016.
20. American Joint Committee on Cancer. Collaborative Stage Data Collection System. 2015; http://www.cancerstaging.org/cstage/.
21. Lym RL, Ostrom QT, Kruchko C, et al. Completeness and concordancy of WHO grade assignment for brain and central nervous system tumors in the United States, 2004-2011. J Neurooncol. 2015.
22. Surveillance Research Program - National Cancer Institute. ICD-0-3 SEER Site/Histology Validation List. 2012; http://seer.cancer.gov/icdo-3/sitetype.icdo3.d20121205.pdf.
23. R Core Team. R: A language and environment for statistical computing. 2018; http://www.R-project.org/.
24. Surveillance Epidemiology and End Results (SEER) Program. SEER∗Stat software version 8.3.5. 2018; www.seer.cancer.gov/seerstat.
25. Lemon J. Plotrix: A package in the red light district of R. R-News. 2006; 6(4):8-12.
26. Wickham H. ggplot2: Elegant graphics for data analysis. 2009; http:// had.co.nz/ggplot2/book.
27. Bivand R, Rundel C. rgeos: Interface to Geometry Engine - Open Source (GEOS). R package version 0.3-11. 2015; http://CRAN.R-project.org/ package=rgeos.
28. Bivand R, Keitt T, Rowlingson B. rgdal: Bindings for the Geospatial Data Abstraction Library. R package version 1.0-4. 2015; http://CRAN.Rproject. org/package=rgdal.
29. Luo J. SEER2R: Reading and writing SEER∗STAT data files. R package version 1.0. 2012; http://CRAN.R-project.org/package=SEER2R.
30. Bivand R, Lewin-Koh N. maptools: Tools for Reading and Handling Spatial Objects. R package version 0.8-36. 2015; http://CRAN.R-project. org/package=maptools.
31. Surveillance Epidemiology and End Results (SEER) Program. SEER∗Stat Database: Populations - Total U.S. (1990-2016) - Linked To County Attributes - Total U.S., 1969-2016 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, Surveillance Systems Branch, released October 2017. http://seer.cancer.gov/popdata/.
32. Tiwari RC, Clegg LX, Zou Z. Efficient interval estimation for age-adjusted cancer rates. Stat Methods Med Res. 2006;15(6):547-569. http://www. ncbi.nlm.nih.gov/pubmed/17260923.
33. NAACCR Race and Ethnicity Work Group. NAACCR Guideline for Enhancing Hispanic/Latino Identification: Revised NAACCR Hispanic/ Latino Identification Algorithm [NHIA v2.2.1]. September 2012.
34. United States Department of Agriculture. 2013 Rural Urban Continuum Codes. 2013; https://www.ers.usda.gov/data-products/rural-urban-continuum-codes/documentation.aspx.
35. Joinpoint Regression Program, Version 4.2.0.2 - June 2015; Statistical Methodology and Applications Branch, Surveillance Research Program, National Cancer Institute.
36. Kim HJ, Fay MP, Feuer EJ, Midthune DN. Permutation tests for joinpoint regression with applications to cancer rates. Stat Med. 2000;19(3):335-351.
37. Zhu L, Pickle LW, Ghosh K, et al. Predicting US- and state-level cancer counts for the current calendar year: Part II: Evaluation of spatiotemporal projection methods for incidence. Cancer. 2012;118(4):1100-1109.
38. Surveillance Epidemiology and End Results (SEER) Program. SEER∗Stat Database: Incidence - SEER 18 Regs Research Data + Hurricane Katrina Impacted Louisiana Cases, Nov 2016 Sub (1973-2015 varying) - Linked To County Attributes - Total U.S., 1969-2016 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, released April 2018, based on the November 2017 submission.
39. Edwards BK, Noone AM, Mariotto AB, et al. Annual Report to the Nation on the status of cancer, 1975-2010, featuring prevalence of comorbidity and impact on survival among persons with lung, colorectal, breast, or prostate cancer. Cancer. 2014; 120(9):1290-1314.
40. Zullig LL, Jackson GL, Dorn RA, et al. Cancer incidence among patients of the U.S. Veterans Affairs Health Care System. Mil Med. 2012;177(6): 693-701.
41. Clegg LX, Feuer EJ, Midthune DN, Fay MP, Hankey BF. Impact of reporting delay and reporting error on cancer incidence rates and trends. J Natl Cancer Inst. 2002;94(20):1537-1545.
42. Midthune DN, Fay MP, Clegg LX, Feuer EJ. Modeling reporting delays and reporting corrections in cancer registry data. J Am Stat Assoc. 2005; 100(469):61-70.
43. Surveillance Epidemiology and End Results (SEER) Program. Cancer Incidence Rates Adjusted for Reporting Delay. 2016; http://surveillance. cancer.gov/delay/.
44. Li XR, Kruchko C, Wu XC, et al. Are benign and borderline brain tumors underreported. J Registry Manag. 2016;43(4):187-194.
45. Anderson RN, Rosenberg HM. Report of the second workshop on age adjustment. Vital Health Stat. 4. 1998(30):I-vi, 1-37.
46. Anderson RN, Rosenberg HM. Age standardization of death rates: Implementation of the year 2000 standard. Natl Vital Stat Rep. 1998; 47(3):1-16, 20.
47. L D, Johnson C, Adams S, Negoita S. Solid Tumor Rules. Rockville, MD: National Cancer Institute; 2018.
48. Johnson C, Peace S, Adamo P, Fritz A, Percy-Laurry A, Edwards B. The 2007 Multiple Primary and Histology Coding Rules. Bethesda, MD: National Cancer Institute; 2007.
49. Ostrom QT, de Blank PM, Kruchko C, et al. Alex's lemonade stand foundation infant and childhood primary brain and central nervous system tumors diagnosed in the United States in 2007-2011. Neuro. Oncol. 2015; 16(Suppl 10):x1-x36.
50. Gurney JG, SM, Bunin GR. Chapter III: CNS and miscellaneous intracranial and intraspinal neoplasms. In: Ries LAG, SM, Gurney JG, et al., eds. Cancer Incidence and Survival among Children and Adolescents: United States SEER Program 1975-1995, National Cancer Institute, SEER Program. NIH Pub. No. 99-4649. Bethesda, MD; 1999.
51. de Blank PM, Ostrom QT, Rouse C, et al. Years of life lived with disease and years of potential life lost in children who die of cancer in the United States, 2009. Cancer Med. 2015.
52. National Cancer Institute at the National Institutes of Health. Adolescents and Young Adults with Cancer. http://www.cancer.gov/ cancertopics/aya.
53. Ostrom QT, Gittleman H, de Blank PM, et al. American brain tumor association adolescent and young adult primary brain and central nervous system tumors diagnosed in the United States in 2008-2012. Neuro Oncol. 2016; 18(Suppl 1):i1-i50.
54. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66(1):7-30.
55. McCarthy BJ, Kruchko C, Dolecek TA. The impact of the Benign Brain Tumor Cancer Registries Amendment Act (Public Law 107-260) on nonmalignant brain and central nervous system tumor incidence trends. J Registry Manag. 2013;40(1):32-35.
56. Gittleman HR, Ostrom QT, Rouse CD, et al. Trends in central nervous system tumor incidence relative to other common cancers in adults, adolescents, and children in the United States, 2000 to 2010. Cancer. 2015; 121(1):102-112.
57. Kshettry VR, Ostrom QT, Kruchko C, Al-Mefty O, Barnett GH, Barnholtz-Sloan JS. Descriptive epidemiology of World Health Organization grades II and III intracranial meningiomas in the United States. Neuro Oncol. 2015;17(8):1166-1173.
58. Zhang AS, Ostrom QT, Kruchko C, Rogers L, Peereboom DM, Barnholtz-Sloan JS. Complete prevalence of malignant primary brain tumors registry data in the United States compared with other common cancers, 2010. Neuro Oncol. 2016.
59. Gittleman H, Boscia A, Ostrom QT, et al. Survivorship in adults with malignant brain and other central nervous system tumor from 2000- 2014. Neuro Oncol. 2018.
60. DevCan: Probability of Developing or Dying of Cancer Software, Version 6.2.0. Statistical Research and Applications Branch, National Cancer Institute, 2007. http://srab.cancer.gov/devcan/ [computer program].
61. Fay MP, Pfeiffer R, Cronin KA, Le C, Feuer EJ. Age-conditional probabilities of developing cancer. Stat Med. 2003;22(11):1837-1848.
62. Fay MP. Estimating age conditional probability of developing disease from surveillance data. Popul Health Metr. 2004;2(1):6.
63. Surveillance Epidemiology and End Results (SEER) Program. DevCan database: "SEER 18 Incidence and Mortality, 2000-2014, with Kaposi Sarcoma and Mesothelioma". National Cancer Institute, DCCPS, Surveillance Research Program, Surveillance Systems Branch, released August 2017, based on the November 2016 submission. Underlying mortality data provided by NCHS.
64. Braganza MZ, Kitahara CM, Berrington de González A, Inskip PD, Johnson KJ, Rajaraman P. Ionizing radiation and the risk of brain and central nervous system tumors: A systematic review. Neuro Oncol. 2012;14(11):1316-1324.
65. Turner MC. Epidemiology: Allergy history, IgE, and cancer. Cancer Immunol Immunother. 2012;61(9):1493-1510.
66. Malmer B, Henriksson R, Grönberg H. Familial brain tumours-genetics or environment? A nationwide cohort study of cancer risk in spouses and first-degree relatives of brain tumour patients. Int J Cancer. 2003;106(2):260-263.
67. Wrensch M, Lee M, Miike R, et al. Familial and personal medical history of cancer and nervous system conditions among adults with glioma and controls. Am J Epidemiol. 1997;145(7):581-593.
68. Malmer B, Grönberg H, Bergenheim AT, Lenner P, Henriksson R. Familial aggregation of astrocytoma in northern Sweden: An epidemiological cohort study. Int J Cancer. 1999;81(3):366-370.
69. Hill DA, Inskip PD, Shapiro WR, et al. Cancer in first-degree relatives and risk of glioma in adults. Cancer Epidemiol Biomarkers Prev. 2003;12(12):1443-1448.
70. Scheurer ME, Etzel CJ, Liu M, et al. Aggregation of cancer in first-degree relatives of patients with glioma. Cancer Epidemiol Biomarkers Prev. 2007;16(11):2491-2495.
71. Ostrom QT, Bauchet L, Davis FG, et al. The epidemiology of glioma in adults: A "state of the science" review. Neuro Oncol. 2014;16(7): 896-913.
72. Johnson KJ, Cullen J, Barnholtz-Sloan JS, et al. Childhood brain tumor epidemiology: A brain tumor epidemiology consortium review. Cancer Epidemiol Biomarkers Prev. 2014;23(12):2716-2736.
73. Wiemels J, Wrensch M, Claus EB. Epidemiology and etiology of meningioma. J Neurooncol. 2010;99(3):307-314.
74. Reifenberger G, Wirsching HG, Knobbe-Thomsen CB, Weller M. Advances in the molecular genetics of gliomas - implications for classification and therapy. Nat Rev Clin Oncol. 2017;14(7):434-452.
75. Cairncross JG, Ueki K, Zlatescu MC, et al. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst. 1998;90(19):1473-1479.
76. Cairncross G, Wang M, Shaw E, et al. Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: Long-term results of RTOG 9402. J Clin Oncol. 2013;31(3):337-343.
77. Vogelbaum MA, Hu C, Peereboom DM, et al. Phase II trial of preirradiation and concurrent temozolomide in patients with newly diagnosed anaplastic oligodendrogliomas and mixed anaplastic oligoastrocytomas: Long term results of RTOG BR0131. J Neurooncol. 2015;124(3):413-420.
78. van den Bent MJ, Brandes AA, Taphoorn MJ, et al. Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: Long-term follow-up of EORTC brain tumor group study 26951. J Clin Oncol. 2013;31(3):344-350.
79. Yan H, Parsons DW, Jin G, et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med. 2009;360(8):765-773.
80. Qi S, Yu L, Li H, et al. Isocitrate dehydrogenase mutation is associated with tumor location and magnetic resonance imaging characteristics in astrocytic neoplasms. Oncol Lett. 2014;7(6):1895-1902.
81. Paldor I, Pearce FC, Drummond KJ, Kaye AH. Frontal glioblastoma multiforme may be biologically distinct from non-frontal and multilobar tumors. J Clin Neurosci. 2016;34:128-132.
82. Ceccarelli M, Barthel FP, Malta TM, et al.; TCGA Research Network. Molecular profiling reveals biologically discrete subsets and pathways of progression in diffuse glioma. Cell. 2016;164(3):550-563.
83. Brat DJ, Verhaak RG, et al.; The Cancer Genome Atlas Research Network. Comprehensive, integrative genomic analysis of diffuse lowergrade gliomas. N Engl J Med. 2015; 372(26):2481-2498.
84. Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005;352(10):997-1003.
85. Hegi ME, Liu L, Herman JG, et al. Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity. J Clin Oncol. 2008;26(25):4189-4199.
86. Stupp R, Hegi ME, Gilbert MR, Chakravarti A. Chemoradiotherapy in malignant glioma: Standard of care and future directions. J Clin Oncol. 2007;25(26):4127-4136.
87. Noushmehr H, Weisenberger DJ, Diefes K, et al.; Cancer Genome Atlas Research Network. Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell. 2010;17(5):510-522.
88. van den Bent MJ, Erdem-Eraslan L, Idbaih A, et al. MGMT-STP27 methylation status as predictive marker for response to PCV in anaplastic Oligodendrogliomas and Oligoastrocytomas. A report from EORTC study 26951. Clin Cancer Res. 2013;19(19):5513-5522.
89. Kool M, Korshunov A, Remke M, et al. Molecular subgroups of medulloblastoma: An international meta-analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, Group 3, and Group 4 medulloblastomas. Acta Neuropathol. 2012;123(4):473-484.
90. Northcott PA, Dubuc AM, Pfister S, Taylor MD. Molecular subgroups of medulloblastoma. Expert Rev Neurother. 2012;12(7):871-884.
91. Northcott PA, Jones DT, Kool M, et al. Medulloblastomics: The end of the beginning. Nat Rev Cancer. 2012;12(12):818-834.
92. Northcott PA, Buchhalter I, Morrissy AS, et al. The wholegenome landscape of medulloblastoma subtypes. Nature. 2017;547(7663):311-317.
93. Jones C, Baker SJ. Unique genetic and epigenetic mechanisms driving paediatric diffuse high-grade glioma. Nat Rev Cancer. 2014; 14(10).
94. Wu G, Diaz AK, Paugh BS, et al. The genomic landscape of diffuse intrinsic pontine glioma and pediatric non-brainstem high-grade glioma. Nat Genet. 2014;46(5):444-450.
95. Mackay A, Burford A, Carvalho D, et al. Integrated molecular metaanalysis of 1000 pediatric high-grade and diffuse intrinsic pontine glioma. Cancer Cell. 2017; 32(4):520-537.e525.
96. Hoffman LM, DeWire M, Ryall S, et al. Spatial genomic heterogeneity in diffuse intrinsic pontine and midline high-grade glioma: Implications for diagnostic biopsy and targeted therapeutics. Acta Neuropathol Commun. 2016;4:1.
97. Grill J, Puget S, Andreiuolo F, Philippe C, MacConaill L, Kieran MW. Critical oncogenic mutations in newly diagnosed pediatric diffuse intrinsic pontine glioma. Pediatr Blood Cancer. 2012;58(4):489-491.
98. Lapin DH, Tsoli M, Ziegler DS. Genomic insights into diffuse intrinsic pontine glioma. Front Oncol. 2017;7:57.
99. Ostrom QT, Gittleman H, Kruchko C, et al. Completeness of required site-specific factors for brain and CNS tumors in the Surveillance, Epidemiology and End Results (SEER) 18 database (2004-2012, varying). J Neuro Oncol. 2016.
100. Weir HK, Johnson CJ, Mariotto AB, et al. Evaluation of North American Association of Central Cancer Registries' (NAACCR) data for use in population-based cancer survival studies. J Natl Cancer Inst Monogr. 2014;2014(49):198-209.
101. Wilson RJ, O'Neil ME, Ntekop E, Zhang K, Ren Y. Coding completeness and quality of relative survival-related variables in the National Program of Cancer Registries Cancer Surveillance System, 1995-2008. J Registry Manag. 2014; 41(2):65-71; quiz 96-67.
102. Kleihues P, Burger PC, Scheithauer BW. The new WHO classification of brain tumours. Brain Pathol. 1993;3(3):255-268.
103. van den Bent MJ. Interobserver variation of the histopathological diagnosis in clinical trials on glioma: A clinician's perspective. Acta Neuropathol. 2010;120(3):297-304.
104. Aldape K, Simmons ML, Davis RL, et al. Discrepancies in diagnoses of neuroepithelial neoplasms: The San Francisco Bay Area Adult Glioma Study. Cancer. 2000;88(10):2342-2349.
105. Sahm F, Reuss D, Koelsche C, et al. Farewell to oligoastrocytoma: In situ molecular genetics favor classification as either oligodendroglioma or astrocytoma. Acta Neuropathol. 2014;128(4):551-559.